Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Opexa Therapeutics, which develops patient-specific cellular therapies for the treatment of autoimmune diseases, has established a multiple sclerosis research partnership with the Myelin Repair Foundation.
Subscribe to our email newsletter
As part of this collaboration, Opexa and the Myelin Repair Foundation (MRF) will work to identify therapeutically relevant biomarkers in multiple sclerosis (MS) that may provide important insight to support the continued development of Tovaxin, Opexa’s T-cell vaccine currently in Phase IIb clinical testing in MS patients.
In addition, biomarkers identified as part of the research program may also assist in guiding the discovery and development of novel diagnostics and treatments for MS.
Under terms of its collaboration with Opexa, the MRF will receive and analyze patient samples and clinical data from Opexa’s Phase IIb clinical study with Tovaxin to identify biomarkers related to safety and efficacy of the therapy in MS patients.
As part of this analysis, the MRF will leverage its network of MS researchers, as well as its proprietary biochemical and biological assays which are designed for the discovery and characterization of novel biomarkers that may have clinical use in diagnosing or treating MS.
The collaboration will be jointly managed by R&D experts from Opexa and the MRF. Under terms of the agreement, each party will own all program intellectual property that is conceived of solely by its representatives.
Intellectual property that is conceived of collaboratively will be jointly owned by both Opexa and the MRF with Opexa retaining the option to negotiate an exclusive license for any of the collaboration’s joint intellectual property or that which is solely owned by the MRF.